Small glass vials being filled in a manufacturing facility

We want your views on Australia’s growing ribonucleic acid (RNA) sector. 

RNA shot to prominence during the COVID-19 pandemic, with the highly effective Moderna and Pfizer vaccines helping save lives. But RNA still has more potential as a vaccine or therapeutic to combat other diseases.

We’re seeking stakeholder views about what is working well within Australia’s RNA sector, and what could be improved. 

Your feedback will:

  • give us insights into Australia’s RNA sector capabilities and priorities for the next 10 years
  • help us understand the challenges and opportunities for the RNA sector in Australia.

Have your say

Read the discussion paper and have your say on our consultation hub. Submissions close on 16 October 2023.